Latest Breaking News On - Sbio inc - Page 3 : vimarsana.com

Rune Price Tops $1.29 (RUNE) | Daily Political

3SBio Inc. (OTCMKTS:TRSBF – Get Rating) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 2,846,900 shares, a decline of 27.4% from the April 15th total of 3,920,400 shares. Based on an average daily volume of 5,100 shares, the days-to-cover ratio is currently […]

3SBio Inc. (OTCMKTS:TRSBF) Short Interest Update

3SBio Inc. (OTCMKTS:TRSBF – Get Rating) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 2,846,900 shares, a decline of 27.4% from the April 15th total of 3,920,400 shares. Based on an average daily volume of 5,100 shares, the short-interest ratio is currently 558.2 days. 3SBio […]

3SBio : 2022 ESG Report | MarketScreener

Stock Code : 1530 Convertible Bonds Code : 40285 2022 Environmental, Social and Governance Report Mission for... | April 28, 2023

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical...

Thrombocytopenia Treatment Market Value to reach US$ 10 Billion by 2033, expected to surge at over 5

A recently published study by FMI expects the global thrombocytopenia treatment market to augment at a 5.2% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 10 Billion is expected for the market. The thrombocytopenia treatment market is predicted to increase significantly, since p...

Form N-CSRS BLACKROCK EUROFUND For: Dec 31

Biosimilars and Follow-on Biologics market is projected to

Visiongain has published a new report entitled Biosimilars and Follow-on Biologics 2023-2033. It includes profiles of Biosimilars and Follow-on Biologics...

Cross-Strait Taiwan Tensions, COVID, And Clinical Trials: An Interview With TLC President Yeh

AnPac Bio Announces Board and Management Changes

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology...

Stock Market | FinancialContent Business Page